Skip to main content
. Author manuscript; available in PMC: 2016 Jul 19.
Published in final edited form as: Arthritis Rheumatol. 2015 Sep;67(9):2457–2465. doi: 10.1002/art.39220

Figure 3.

Figure 3

Odds ratios for serious adverse events (SAEs) in patients assigned to the active treatment group as compared to the placebo group, stratified by diagnosis (connective tissue disease–associated pulmonary arterial hypertension [CTD-PAH] and idiopathic PAH [IPAH]). Odds ratios are shown with 95% confidence intervals. There was no significant difference in the occurrence of treatment-related SAEs between the CTD-associated PAH and idiopathic PAH groups. Color figure can be viewed in the online issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.39220/abstract.